SymBiosis

Harmonix invests in technological breakthroughs that will help create a future for a healthy, operational, and peaceful civilization. The fund focuses on exceptional entrepreneurs and innovative healthcare, life sciences, and deep tech companies. Harmonix is a multi-disciplinary team comprising scientists, researchers, operators, entrepreneurs, and industry experts with over 70 years of cumulative experience. Our diverse team provides founders with deep technical, operating, industry, and advisory expertise to accelerate and commercialize the next generation of technological advances. Harmonix accelerates scientific discoveries to advance human health and technology. We invest in companies that have functional solutions to real world problems. The Harmonix Process We deploy an evidence-based due diligence framework in assessing companies. Research: We identify opportunities ripe for innovation and examine areas where current standards of R&D, care, treatment, or workflow processes are inadequate. We find companies with functional solutions to problems that can create real value for stakeholders. Invest: We assess not only the technical dimensions of a venture, including supporting proof-of-concept data but also founder-fund fit. Our team looks for founders with emotional intelligence and demonstrated capacity for leadership and integrity. Accelerate: We support founders in all realms of the entrepreneurial process, including technical, operational, and business development support. We offer access to advisors who provide a level of expertise that is unavailable to many early-stage scientific companies.

Luma Group is passionately leading a transformation in healthcare, driven by a deep-seated commitment to enhance human health. We’re on a mission to turn visionary science into revolutionary healthcare solutions. Our team unites a dynamic mix of investors, scientists, clinicians, and entrepreneurs, all dedicated to advancing human health outcomes. We are not just funding remarkable scientific discoveries; we are investing in the future of humanity. Our focus is on nurturing groundbreaking innovations leveraging advanced computation and artificial intelligence that promise to redefine healthcare, ensuring that every investment we make contributes to a healthier, brighter future for all. Our approach is hands-on and collaborative, partnering with the brightest minds in science, clinical research, engineering, and entrepreneurship. We’re not just investors; we’re co-creators, working side-by-side with innovators and dreamers to transform cutting-edge scientific discoveries into groundbreaking therapeutics, diagnostics, and medical devices. Our goal is clear: to make a significant and lasting impact on human health. Every project we embark on is a step towards redefining what’s possible in healthcare, ensuring that we’re not just part of the conversation, but leading the charge in creating a healthier future for everyone.

Our deep resources and industry knowledge make us the ideal partner to scientists and entrepreneurs worldwide. Pivotal Life Sciences is an investment platform that specializes in providing capital to innovative companies developing therapeutic products and technologies to address major unmet medical needs. The name “Pivotal” synthesizes our investment approach with the role we strive to play in the companies we invest in. Our strategy is to invest in companies of all stages, with a primary focused on “high impact” therapeutics – solutions that address growing unmet medical needs and with near-curative or otherwise transformative disease management potential. We look for companies at the cusp of their greatest de-risking value inflection point and strive to play a key role in company building alongside management.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

Our mission is to serve as a catalyst for innovation by providing early-stage strategic capital and expert guidance to visionary entrepreneurs and researchers. We're committed to propelling revolutionary technologies and treatments poised to transform healthcare and significantly enhance the lives of patients and their families. About Us At Shannon Life Sciences, we are driven by a passion for innovation. We specialize in identifying and supporting early, groundbreaking ideas that have the potential to revolutionize the treatment of patients. Our team is a mosaic of experts in healthcare, finance, and entrepreneurship. This diverse expertise, coupled with a deep understanding of the healthcare sector and the intricacies of bringing novel therapies to market, positions us to help enable our portfolio companies to be successful. Our role extends beyond funding. We actively engage with academic institutions, visionary entrepreneurs, and industry leaders, forging partnerships that propel cutting-edge therapies and technologies into the healthcare arena.

Santé is a leading early-stage venture capital firm founded in 2006, with offices in Austin and Boston. We invest at the intersection of science and technology, catalyzing disruptive opportunities across Biotech, MedTech and HealthTech. Combining extensive healthcare industry experience with deep scientific and technical expertise, we pursue innovative new opportunities to improve lives and generate returns. At Santé, we fuel entrepreneurs and form next-generation companies which shape the future of patient care, delivering better healthcare outcomes at a lower total cost to the system. Our expertise spans cellular biology, pharmaceutical drug development, device design and engineering, physician and hospital leadership, and public policy. Our investment philosophy of disciplined fund size, significant ownership positions, and diversified life sciences exposure has proven successful, as our funds have consistently generated top quartile returns for our investors. The firm has nearly $1BN under management and is investing out of Santé Health Ventures IV (a 2021 vintage fund) which follows the same successful investment strategy as our prior funds.